Brain angiotensin and dopaminergic degeneration: Relevance to Parkinson’s disease

American Journal of Neurodegenerative Diseases

Volumn 1, Issue 3, 2012, Pages 226-244

  Labandeira Garcia, Jose L ^a,b   Rodriguez Pallares, Jannette ^a,b   Rodríguez Perez, Ana I ^a,b   Garrido Gil, Pablo ^a,b   Villar Cheda, Begoña ^a,b   Valenzuela, Rita ^a,b   Guerra, Maria J ^a,b  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Aging; Angiotensin; Degenerative disease; Dopamine; Menopause; Neurodegeneration; Neuroinflammation; Oxidative stress; Parkinson; Renin angiotensin system

Indexed keywords

ANGIOTENSIN; PRORENIN RECEPTOR; VASCULOTROPIN;

AUTORADIOGRAPHY; BRAIN PERFUSION; CELL DEATH; CONFOCAL MICROSCOPY; DEGENERATIVE DISEASE; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; NERVOUS SYSTEM INFLAMMATION; NEUROMODULATION; NEUROPROTECTION; OXIDATIVE STRESS; PARKINSON DISEASE; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; UPREGULATION;

EID: 84980053727     PISSN: None     EISSN: 2165591X     Source Type: Journal    
DOI: None     Document Type: Review

References (212)

1. Allen AM, Moeller I, Jenkins A, Zhuo J, Aldred GP, Chai SY, Mendelsohn FAO. Angiotensin receptors in the nervous system. Brain Res Bull 1998; 47: 17-8.
2. Unger T, Chung O, Csikos T, Culman J, Gallinat S, Gohlke P, Höhle S, Meffert S, Stoll M, Stroth U, Zhu Y-Z. Angiotensin receptors. J Hypertens 1996; 14 (suppl. 5): S95-103.
3. Kambayashi Y, Bardhan S, Takahashi K, Tsuzuki S, Inui H, Hamakubo T, Inagami T. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem 1993; 268: 24543-24546.
4. Nakajima M, Mukoyama M, Pratt RE, Horiuchi M, Dzau VJ. Cloning of cDNA and analysis of the gene for mouse angiotensin II type 2 receptor. Biochem Biophys Res Commun 1993; 197: 393-399.
5. Gard PR. The role of angiotensin II in cognition and behaviour. Eur J Pharmacol 2002; 438: 1- 14.
6. Rosenstiel P, Gallinat S, Arlt A, Unger T, Sievers J, Lucius R. Angiotensin AT2 receptor ligands: do they have potential as future treatments for neurological disease? CNS Drugs 2002; 16: 145-153.
7. Rodriguez-Pallares J, Quiroz CR, Parga JA, Guerra MJ, Labandeira-Garcia JL. Angiotensin II increases differentiation of dopaminergic neurons from mesencephalic precursors via angiotensin type 2 receptors. Eur J Neurosci 2004; 20: 1489-1498.
8. Steckelings UM, Kaschina E, Unger T. The AT2 receptor--a matter of love and hate. Peptides 2005; 26: 1401-1409.
9. Chabrashvili T, Kitiyakara C, Blau J, Karber A, Islam S, Welch WJ, Wilcox CF. Effect of Ang II type 1 and 2 receptors on oxidative stress, renal NAD(P)H oxidase, and SOD expresion. Am J Physisiol Regu Integr Comp Physiol 2003; 285: R117-124.
10. Jones ES, Vinh A, McCarthy CA, Gaspari TA, Widdop RE. AT2 receptors: functional relevance in cardiovascular disease. Pharmacol Ther 2008; 120: 292-316.
11. Smith HW. From fish to phylosopher. Boston: Little, Brown; 1953.
12. Lev-Ran A, Porta M. Salt and hypertension: a phylogenetic perspective. Diabetes Metab Res Rev 2005; 21: 118-131.
13. Tigerstedt R, Bergman P. Niere und Kreislauf. Skand Arch Physiol 1898; 8: 223-271.
14. Braun-Menendez E, Fasciolo JC, Leloir LF, Muñoz JM. The substance causing renal hypertension. J Physiol 1940; 98: 283-298.
15. Page IH, Helmer OM. A crystalline pressor substance (angiotonin) resulting from the reaction between renin and renin-activator. J Exp Med 1940; 71: 29-42.
16. Ganong WF. Origin of the angiotensin II secreted by cells. Proc Soc Exp Biol Med 1994; 205: 213-219.
17. Re RN. Tissue renin angiotensin systems. Med Clin North Am 2004; 88: 19-38.
18. Ruiz-Ortega M, Lorenzo O, Ruperez M, Suzuki Y, Egido J. Proinflammatory actions of angiotensin II. Curr Opin Nephrol Hypertens 2001; 10: 321- 329.
19. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003; 35: 881- 900.
20. Touyz RM. Reactive oxygen species and angiotensin II signaling in vascular cells-implications in cardiovascular disease. Braz J Med Biol Res 2004; 37: 1263-1273.
21. Zalba G, San Jose G, Moreno MU, Fortuño MA, Fortuño A, Beaumont FJ, Diez J. Oxidative stress in arterial hypertension. Role of NADPH oxidase. Hypertension 2001; 38: 1395-1399.
22. Garrido AM, Griendling KK. NADPH oxidases and angiotensin II receptor signaling. Mol Cell Endocrinol 2009; 302: 148-158.
23. Babior B. NADPH oxidase: an update. Blood 1999; 93: 1464-1476.
24. Babior BM. NADPH oxidase. Curr Opin Immunol 2004; 16: 42-47.
25. Cai H. NAD(P)H oxidase-dependent selfpropagation of hydrogen peroxide and vascular disease. Circ Res 2005; 96: 818-822.
26. Alberici LC, Oliveira HC, Paim BA, Mantello CC, Augusto AC, Zecchin KG, Gurgueira SA, Kowaltowski AJ, Vercesi AE. Mitochondrial ATPsensitive K(+) channels as redox signals to liver mitochondria in response to hypertriglyceridemia. Free Radic Biol Med 2009; 47: 1432- 1439.
27. Sheh YL, Hsu C, Chan SH, Chan JY. NADPH oxidase- and mitochondrion-derived superoxide at rostral ventrolateral medulla in endotoxininduced cardiovascular depression. Free Radic Biol Med 2007; 42: 1610-1623.
28. Zhang GX, Lu XM, Kimura S, Nishiyama A. Role of mitochondria in angiotensin II-induced reactive oxygen species and mitogen-activated protein kinase activation. Cardiovasc Res 2007; 76: 204-212.
29. Griendling KK, Sorescu D, Ushio-Fukai M. NADPH oxidase. Role in cardiovascular biology and disease. Circulation Res 2000; 86: 494- 501.
30. Münzel T, Keany JF. Are ACE inhibitors a "magic bullet" against oxidative stress? Circulation 2001; 104: 1571-1577.
31. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-9.
32. Hamming I, Cooper ME, Haagmans BL, Hooper NM, Korstanje R, Osterhaus AD, Timens W, Turner AJ, Navis G, van Goor H. The emerging role of ACE2 in physiology and disease. J Pathol 2007; 212: 1-11.
33. Bacani C, Frishman WH. Chymase: a new pharmacologic target in cardiovascular disease. Cardiol Rev 2006; 14: 187-193.
34. Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T, Lee J, Mendelsohn FA, Simpson RJ, Connolly LM, Chai SY. Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem 2001; 276: 48623-48626.
35. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 2003; 100: 8258-8263.
36. Clark MA, Diz DI, Tallant EA. Angiotensin-(1-7) downregulates the angiotensin II type 1 receptor in vascular smooth muscle cells. Hypertension 2001; 37: 1141-1146.
37. Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-Walther S, Sexton PM, Gembardt F, Kellett E, Martini L, Vanderheyden P, Schultheiss HP, Walther T. G-protein-coupled receptor Mas is a physiological antagonist of the angiotensin II type 1 receptor. Circulation 2005; 111: 1806-1813.
38. Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/ prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109: 1417-1427.
39. Nguyen G. Renin, (pro)renin and receptor: an update. Clin Sci (Lond) 2011; 120: 169-178.
40. Nguyen G. Renin/prorenin receptors. Kidney Int 2006; 69: 1503-1506.
41. Achard V, Boullu-Ciocca S, Desbriere R, Nguyen G, Grino M. Renin receptor expression in human adipose tissue. Am J Physiol Regul Integr Comp Physiol 2007; 292: R274-282.
42. Ichihara A, Suzuki F, Nakagawa T, Kaneshiro Y, Takemitsu T, Sakoda M, Nabi AH, Nishiyama A, Sugaya T, Hayashi M, Inagami T. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J Am Soc Nephrol 2006; 17: 1950-1961.
43. Nguyen G, Contrepas A. The (pro)renin receptors. J Mol Med 2008; 86: 643-646.
44. Nguyen G, Burcklé CA, Sraer JD. Renin/prorenin -receptor biochemistry and functional significance. Curr Hypertens Rep 2004; 6: 129-132.
45. Schefe JH, Menk M, Reinemund J, Effertz K, Hobbs RM, Pandolfi PP, Ruiz P, Unger T, Funke- Kaiser H. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res 2006; 99: 1355-1366.
46. Shan Z, Cuadra AE, Sumners C, Raizada MK. Characterization of a functional (pro)renin receptor in rat brain neurons. Exp Physiol 2008; 93: 701-718.
47. Ichihara A, Hayashi M, Kaneshiro Y, Suzuki F, Nakagawa T, Tada Y, Koura Y, Nishiyama A, Okada H, Uddin MN, Nabi AH, Ishida Y, Inagami T, Saruta T. Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest 2004; 114: 1128-1135.
48. Kaneshiro Y, Ichihara A, Sakoda M, Takemitsu T, Nabi AH, Uddin MN, Nakagawa T, Nishiyama A, Suzuki F, Inagami T, Itoh H. Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)renin receptor-transgenic rats. J Am Soc Nephrol 2007; 18: 1789-1795.
49. Baker KM, Chernin MI, Schreiber T, Sanghi S, Haiderzaidi S, Booz GW, Dostal DE, Kumar R. Evidence of a novel intracrine mechanism in angiotensin II-induced cardiac hypertrophy. Regul Pept 2004; 120: 5-13.
50. Chen R, Mukhin YV, Garnovskaya MN, Thielen TE, Iijima Y, Huang C, Raymond JR, Ullian ME, Paul RV. A functional angiotensin II receptor- GFP fusion protein: evidence for agonistdependent nuclear translocation. Am J Physiol Renal Physiol 2000; 279: F440-448.
51. Eggena P, Zhu JH, Sereevinyayut S, Giordani M, Clegg K, Andersen PC, Hyun P, Barrett JD. Hepatic angiotensin II nuclear receptors and transcription of growth-related factors. J Hypertens 1996; 14: 961-968.
52. Lu D, Yang H, Shaw G, Raizada MK. Angiotensin II-induced nuclear targeting of the angiotensin type 1 (AT1) receptor in brain neurons. Endocrinology 1998; 139: 365-375.
53. Kumar R, Singh VP, Baker KM. The intracellular renin-angiotensin system: a new paradigm. Trends Endocrinol Metab 2007; 18: 208-214.
54. Kumar R, Singh VP, Baker KM. The intracellular renin-angiotensin system in the heart. Curr Hypertens Rep 2009; 11: 104-110.
55. Saavedra JM. Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities. Cell Mol Neurobiol 2005; 25: 485-512.
56. von Bohlen und Halbach O, Albrecht D. The CNS renin-angiotensin system. Cell Tissue Res 2006; 326: 599-616.
57. Phillips MI, de Oliveira EM. Brain renin angiotensin in disease. J Mol Med 2008; 86: 715- 722.
58. Cuadra AE, Shan Z, Sumners C, Raizada MK. A current view of brain renin-angiotensin system: Is the (pro)renin receptor the missing link? Pharmacol Ther 2010; 125: 27-38.
59. Harding JW, Sullivan MJ, Hanesworth JM, Cushing LL, Wright JW. Inability of [125I]Sar1, Ile8- angiotensin II to move between the blood and cerebrospinal fluid compartments. J Neurochem 1988; 50: 554-557.
60. Hermann K, McDonald W, Unger T, Lang RE, Ganten D. Angiotensin biosynthesis and concentrations in brain of normotensive and hypertensive rats. J Physiol (Paris) 1984; 79: 471- 480.
61. Stornetta RL, Hawelu-Johnson CL, Guyenet PG, Lynch KR. Astrocytes synthesize angiotensinogen in brain. Science 1988; 242: 1444-1446.
62. Milsted A, Barna BP, Ransohoff RM, Brosnihan KB, Ferrario CM. Astrocyte cultures derived from human brain tissue express angiotensinogen mRNA. Proc Natl Acad Sci USA 1990; 87: 5720-5723.
63. Kumar A, Rassoli A, Raizada MK. Angiotensinogen gene expression in neuronal and glial cells in primary cultures of rat brain. J Neurosci Res 1988; 19: 287-290.
64. Thomas WG, Greenland KJ, Shinkel TA, Sernia C. Angiotensinogen is secreted by pure rat neuronal cell cultures. Brain Res 1992; 588: 191- 200.
65. Ganten D, Minnich JL, Granger P, Hayduk K, Brecht HM, Barbeau A, Boucher R, Genest J. Angiotensin-forming enzyme in brain tissue. Science 1971; 173: 64-65.
66. Fuxe K, Ganten D, Hökfelt T, Locatelli V, Poulsen K, Stock G, Rix E, Taugner R. Renin-like immunocytochemical activity in the rat and mouse brain. Neurosci Lett 1980; 18: 245- 250.
67. Dzau VJ, Brenner A, Emmett NL. Evidence for renin in rat brain: differentiation from other renin like enzymes. Am J Physiol 1982; 242: E292-E297.
68. Slater EE, Defendini R, Zimmerman EA. Wide distribution of immunoreactive renin in nerve cells of human brain. Proc Natl Acad Sci USA 1980; 77: 5458-5460.
69. Dzau VJ, Ingelfinger J, Pratt RE, Ellison KE. Identificacion of renin and angiotensinogen messenger RNA sequences in mouse and rat brains. Hypertension 1986; 8: 544-548.
70. Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A, Boe AF, Boguski MS, Brockway KS, Byrnes EJ, Chen L, Chen L, Chen TM, Chin MC, Chong J, Crook BE, Czaplinska A, Dang CN, Datta S, Dee NR, Desaki AL, Desta T, Diep E, Dolbeare TA, Donelan MJ, Dong HW, Dougherty JG, Duncan BJ, Ebbert AJ, Eichele G, Estin LK, Faber C, Facer BA, Fields R, Fischer SR, Fliss TP, Frensley C, Gates SN, Glattfelder KJ, Halverson KR, Hart MR, Hohmann JG, Howell MP, Jeung DP, Johnson RA, Karr PT, Kawal R, Kidney JM, Knapik RH, Kuan CL, Lake JH, Laramee AR, Larsen KD, Lau C, Lemon TA, Liang AJ, Liu Y, Luong LT, Michaels J, Morgan JJ, Morgan RJ, Mortrud MT, Mosqueda NF, Ng LL, Ng R, Orta GJ, Overly CC, Pak TH, Parry SE, Pathak SD, Pearson OC, Puchalski RB, Riley ZL, Rockett HR, Rowland SA, Royall JJ, Ruiz MJ, Sarno NR, Schaffnit K, Shapovalova NV, Sivisay T, Slaughterbeck CR, Smith SC, Smith KA, Smith BI, Sodt AJ, Stewart NN, Stumpf KR, Sunkin SM, Sutram M, Tam A, Teemer CD, Thaller C, Thompson CL, Varnam LR, Visel A, Whitlock RM, Wohnoutka PE, Wolkey CK, Wong VY, Wood M, Yaylaoglu MB, Young RC, Youngstrom BL, Yuan XF, Zhang B, Zwingman TA, Jones AR. Genome-wide atlas of gene expression in the adult mouse brain. Nature 2007; 445: 168-176.
71. Morimoto S, Cassell MD, Sigmund CD. The brain renin-angiotensin system in transgenic mice carrying a highly regulated human renin transgene. Cir Res 2002; 90: 80-86.
72. Bader M and Ganten D. It's renin in the brain. Transgenic animals elucidate the brain reninangiotensin system. Circ Res 2002; 90: 8-10.
73. Lavoie JL, Cassell MD, Gross KW, Sigmund CD. Localization of renin expressing cells in the brain, by use of a REN-eGFP transgenic model. Physiol Genomics 2004; 16: 240-246.
74. Allen AM, O'Callaghan EL, Hazelwood L, Germain S, Castrop H, Schnermann J, Bassi JK. Distribution of cells expressing human reninpromoter activity in the brain of a transgenic mouse. Brain Res 2008; 1243: 78-85.
75. Valenzuela R, Barroso-Chinea P, Muñoz A, Joglar B, Villar-Cheda B, Lanciego JL, Labandeira-Garcia JL. Location of prorenin receptors in primate substantia nigra: effects on dopaminergic cell death. J Neuropathol Exp Neurol 2010; 69: 1130-1142.
76. Luetscher JA, Kraemer FB, Wilson DM, Schwartz HC, Bryer-Ash M. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications. N Engl J Med 1985; 312: 1412-1417.
77. Noh KM, Koh JY. Induction and activation by zinc of NADPH oxidase in cultured cortical neurons and astrocytes. J Neurosci 2000; 20: RC111 (1-5).
78. Wang G, Anrather J, Huang J, Speth RC, Pickel V, Iadecola C. NADPH oxidase contributes to angiotensin II signalling in the nucleus tractus solitarius. J Neurosci 2004; 24: 5516-5524.
79. Gao HM, Liu B, Zhang W, Hong JS. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J 2003; 17: 1954-1956.
80. Wu D, Teisman P, Tieu K, Vila M, Jackson-Lewis V, Ischiropoulos H, Przedborski S. NADPH oxidase mediates oxidative stress in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci USA 2003; 100: 6145-6150.
81. Allen AM, MacGregor DP, Chai SY, Donnan GA, Kaczymarzyk S, Richardson K, Kalnins R, Ireton J, Mendelsohn FAO. Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia. Ann Neurol 1992; 32: 339-344.
82. Lenkei Z, Palkovits M, Corvol P, Llorens-Cortes C. Expression of angiotensin type-1 (AT1) and type 2 (AT2) receptor mRNAs in the adult rat brain: A functional neuroanatomical review. Front Neuroendocrinol 1997; 18: 383-339.
83. Simonnet G, Giorguieff-Chesselet MF, Carayon A, Bioulac B, Cesselin F, Glowinski J, Vincent JD. Angiotensin II and the nigrostriatal system. J Physiol 1981; 77: 71-79.
84. Rodriguez-Pallares J, Rey P, Parga JA, Muñoz A, Guerra MJ, Labandeira-Garcia JL. Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS. Neurobiol Dis 2008; 31: 58-73.
85. Joglar B, Rodriguez-Pallares J, Rodríguez-Perez AI, Rey P, Guerra MJ, Labandeira-Garcia JL. The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. J Neurochem 2009; 109: 656-669.
86. Garrido-Gil P, Valenzuela R, Villar-Cheda B, Lanciego JL, Labandeira-Garcia JL. Expression of angiotensinogen and receptors for angiotensin and prorenin in the monkey and human substantia nigra: an intracellular reninangiotensin system in the nigra. Brain Struct Funct 2012.
87. Quinlan JT, Phillips MI. Immunoreactivity for angiotensin II-like peptide in the human brain. Brain Res 1981; 205: 212-218.
88. Brownfield MS, Reid IA, Ganten D, Ganong WF. Differential distribution of immunoreactive angiotensin and angiotensin-converting enzyme in rat brain. Neuroscience 1982; 7: 1759-1769.
89. Chai SY, Mendelsohn FAO, Paxinos G. Angiotensin converting enzyme in rat brain visualized by quantitative in vitro autoradiography. Neuroscience 1987; 20: 615-627.
90. Rodriguez-Pallares J, Parga JA, Muñoz A, Rey P, Guerra MJ, Labandeira-Garcia JL. Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6- hydroxydopamine-induced degeneration of dopaminergic neurons. J Neurochem 2007; 103: 145-156.
91. Re RN. Intracellular renin and the nature of intracrine enzymes. Hypertension 2003; 42: 117-122.
92. Csiszar A, Ungvari Z, Koller A, Edwards JG, Kaley G. Aging-induced proinflammatory shift in cytokine expression profile in coronary arteries. FASEB J 2003; 17: 1183-1185.
93. Ungvari Z, Csiszar A, Kaley G. Vascular inflammation in aging. Herz 2004; 29: 733-740.
94. Choi DY, Zhang J, Bing G. Aging enhances the neuroinflammatory response and alphasynuclein nitration in rats. Neurobiol Aging 2010; 31: 1649-1653.
95. Heymes C, Silvestre JS, Llorens-Cortes C, Chevalier B, Marotte F, Levy BI, Swynghedauw B, Samuel JL. Cardiac senescence is associated with enhanced expression of angiotensin II receptor subtypes. Endocrinology 1998; 139: 2579-2587.
96. Touyz RM, Endemann D, He G, Li JS, Schiffrin EL. Role of AT2 receptors in angiotensin IIstimulated contraction of small mesenteric arteries in young SHR. Hypertension 1999; 33: 366-372.
97. Mukai Y, Shimokawa H, Higashi M, Morikawa K, Matoba T, Hiroki J, Kunihiro I, Talukder HM, Takeshita A. Inhibition of renin-angiotensin system ameliorates endothelial dysfunction associated with aging in rats. Arterioscler Thromb Vasc Biol 2002; 22: 1445-1450.
98. Basso N, Paglia N, Stella I, de Cavanagh EM, Ferder L, del Rosario Lores Arnaiz M, Inserta F. Protective effect of the inhibition of the reninangiotensin system on aging. Regul Pept 2005; 128: 247-252.
99. de Cavanagh EM, Piotrkowski B, Fraga CG. Concerted action of the renin-angiotensin system, mitochondria, and antioxidant defenses in aging. Mol Aspects Med 2004; 25: 27-36.
100. de Cavanagh EM, Inserra F, Ferder L. Angiotensin II blockade: a strategy to slow ageing by protecting mitochondria? Cardiovasc Res 2011; 89: 31-40.
101. Thompson MM, Oyama TT, Kelly FJ, Kennefick TM, Anderson S. Activity and responsiveness of the renin-angiotensin system in the aging rat. Am J Physiol Regul Integr Comp Physiol 2000; 279: R1787-1794.
102. Cassis P, Conti S, Remuzzi G, Benigni A. Angiotensin receptors as determinants of life span. Pflugers Arch 2010; 459: 325-332.
103. Min LJ, Mogi M, Iwai M, Horiuchi M. Signaling mechanisms of angiotensin II in regulating vascular senescence. Ageing Res Rev 2009; 8: 113-121.
104. de Cavanagh EM, Inserra F, Ferder M, Ferder L. From mitochondria to disease: role of the reninangiotensin system. Am J Nephrol 2007; 27: 545-553.
105. Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, Conti S, Rottoli D, Longaretti L, Cassis P, Morigi M, Coffman TM, Remuzzi G. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest 2009; 119: 524- 530.
106. Umemoto S. Angiotensin II type 1 (AT1) receptor deficiency halts the progression of agerelated atherosclerosis in hypercholesterolemia: molecular link between the AT1 receptor and hypercholesterolemia. Hypertens Res 2008; 31: 1495-1497.
107. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol 2007; 292: C82-97.
108. Qin L, Liu Y, Wang T, Wei SJ, Block ML, Wilson B, Liu B, Hong JS. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J Biol Chem 2004; 279: 1415-1421.
109. Benigni A, Cassis P, Remuzzi G. Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Mol Med 2010; 2: 247- 257.
110. Marchesi C, Paradis P, Schiffrin EL. Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci 2008; 29: 367-374.
111. Peng J, Kimura B, Phillips MI. The predominant role of brain angiotensinogen and angiotensin in environmentally induced hypertension. Regul Pept 2002; 110: 25-32.
112. Saab YB, Gard PR, Yeoman MS, Mfarrej B, El-Moalem H, Ingram MJ. Renin-angiotensinsystem gene polymorphisms and depression. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1113-1118.
113. Maul B, Krause W, Panlow K, Becker M, Gembardt F, Alenina N, Walther T, Bader M, Siems WE. Central angiotensin II controls alcohol consumption via its AT1 receptor. FASEB J 2005; 19: 1474-1481.
114. Kerr DS, Bevilaqua LR, Bonini JS, Rossato JI, Köhler CA, Medina JH, Izquierdo I, Cammarota M. Angiotensin II blocks memory consolidation through an AT2 receptor-dependent mechanism. Psychopharmacology (Berl) 2005; 179: 529-535.
115. Hellner K, Walther T, Schubert M, Albrecht D. Angiotensin-(1-7) enhances LTP in the hippocampus through the G-protein-coupled receptor Mas. Mol Cell Neurosci 2005; 29: 427-435.
116. Serrano F, Kolluri NS, Wientjes FB, Card JP, Klann E. NADPH oxidase immunoreactivity in the mouse brain. Brain Res 2003; 998: 193- 198.
117. Kim MJ, Shin KS, Chung YB, Jung KW, Cha CI, Shin DH. Immunohistochemical study of p47Phox and gp91Phox distributions in rat brain. Brain Res 2005; 1040: 178-186.
118. Platten M, Youssef S, Hur EM, Ho PP, Han MH, Lanz TV, Phillips LK, Goldstein MJ, Bhat R, Raine CS, Sobel RA, Steinman L. Blocking angiotensin- converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc Natl Acad Sci USA 2009; 106: 14948-14953.
119. Stegbauer J, Lee DH, Seubert S, Ellrichmann G, Manzel A, Kvakan H, Muller DN, Gaupp S, Rump LC, Gold R, Linker RA. Role of the reninangiotensin system in autoimmune inflammation of the central nervous system. Proc Natl Acad Sci USA 2009; 106: 14942-14947.
120. Kehoe PG, Wilcock GK. Is inhibition of the renin -angiotensin system a new treatment option for Alzheimer's disease? Lancet Neurol 2007; 6: 373-378.
121. Mogi M, Horiuchi M. Effects of angiotensin II receptor blockers on dementia. Hypertens Res 2009; 32: 738-740.
122. Lou M, Blume A, Zhao Y, Gohlke P, Deuschl G, Herdegen T, Culman J. Sustained blockade of brain AT1 receptors before and after focal cerebral ischemia alleviates neurologic deficits and reduces neuronal injury, apoptosis, and inflammatory responses in the rat. J Cereb Blood Flow Metab 2004; 24: 536-547.
123. Iwanami J, Mogi M, Tsukuda K, Min LJ, Sakata A, Jing F, Iwai M, Horiuchi M. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptorgamma activation in diabetic mice. J Hypertens 2010; 28: 1730-1737.
124. Carlsson A, Falck B, Hillarp NA. Cellular localization of brain monoamines. Acta Physiol Scand Suppl 1962; 56: 1-28.
125. Khan F, Spicarová Z, Zelenin S, Holtbäck U, Scott L, Aperia A. Negative reciprocity between angiotensin II type 1 and dopamine D1 receptors in rat renal proximal tubule cells. Am J Physiol Renal Physiol 2008; 295: F1110-1116.
126. Gildea JJ. Dopamine and angiotensin as renal counterregulatory systems controlling sodium balance. Curr Opin Nephrol Hypertens 2009; 18: 28-32.
127. Zeng C, Liu Y, Wang Z, He D, Huang L, Yu P, Zheng S, Jones JE, Asico LD, Hopfer U, Eisner GM, Felder RA, Jose PA. Activation of D3 dopamine receptor decreases angiotensin II type 1 receptor expression in rat renal proximal tubule cells. Circ Res 2006; 99: 494-500.
128. Li H, Armando I, Yu P, Escano C, Mueller SC, Asico L, Pascua A, Lu Q, Wang X, Villar VA, Jones JE, Wang Z, Periasamy A, Lau YS, Soaresda-Silva P, Creswell K, Guillemette G, Sibley DR, Eisner G, Gildea JJ, Felder RA, Jose PA. Dopamine 5 receptor mediates Ang II type 1 receptor degradation via a ubiquitin-proteasome pathway in mice and human cells. J Clin Invest 2008; 118: 2180-2189.
129. Mendelsohn FAO, Jenkins TA, Berkovic SF. Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rat. Brain Res 1993; 613: 221-229.
130. Brown DC, Steward LJ, Ge J, Barnes NM. Ability of angiotensin II to modulate striatal dopamine release via AT1 receptor in vitro and in vivo. British J Pharmacol 1996; 18: 414-420.
131. Hussain T, Abdul-Wahab R, Kotak DK, Lokhandwala MF. Bromocriptine regulates angiotensin II response on sodium pump in proximal tubules. Hypertension 1998; 32: 1054-1059.
132. Zeng C, Zhang M, Asico LD, Eisner GM, Jose PA. The dopaminergic system in hypertension. Clin Sci (Lond) 2007; 112: 583-597.
133. Jenkins TA, Mendelsohn FAO, Chai SY. Angiotensin- converting enzyme modulates dopamine turnover in the striatum. J Neurochem 1997; 68: 1304-1311.
134. Jenkins TA, Wong JYF, Howells DW, Mendelsohn FAO. Effect of chronic angiotens in converting enzyme inhibition on striatal dopamine content in MPTP-treated mouse. J Neurochem 1999; 73: 214-219.
135. Reardon KA, Mendelsohn FA, Chai SY, Horne MK. The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson's disease. Aust N Z Med 2000; 30: 48-53.
136. Villar-Cheda B, Rodríguez-Pallares J, Muñoz A, Valenzuela R, Guerra MJ, Baltatu OC, Labandeira-Garcia JL. Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: implications for progression of Parkinson's disease. Eur J Neurosci 2010; 32: 1695-1706.
137. Gelband CH, Zhu M, Lu D, Reagan LP, Fluharty SJ, Posner P, Raizada MK, Sumners C. Functional interactions between neuronal AT1 and AT2 receptors. Endocrinology 1997; 138: 2195 -2198.
138. Ferrari R, Guardigli G, Cicchitelli G, Valgimigli M, Merli E, Soukhomorskaia O, Ceconi C. Angiotensin II overproduction: enemy of the vessel wall. Eur Heart J 2002; 4 Suppl A: A26-A30.
139. Olanow CW. The pathogenesis of cell death in Parkinson's disease. Mov Disord 2007; 22 Suppl 17: S335-342.
140. Andersen JK. Oxidative stress in neurodegeneration: cause or consequence. Nat Med 2004; 10: S18-25.
141. Berg D, Youdim MB, Riederer P. Redox imbalance. Cell Tissue Res 2004; 318: 201-213.
142. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 1990; 40 Suppl 3: 32-39.
143. Fahn S, Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann Neurol 1992; 32: 804-812.
144. Vila M, Jackson-Lewis V, Guegan C, Wu DC, Teismann P, Choi DK, Tieu K, Przedborski S. The role of glial cells in Parkinson's disease. Curr Opin Neurol 2001; 14: 483-489.
145. Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E and Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6- OHDA dopamine degeneration in rats monitored by immunohisto-chemistry and PET imaging. Eur J Neurosci 2002; 15: 991-998.
146. Depino AM, Earl C, Kaczmarczyk E, Ferrari C, Besedovsky H, del Rey A, Pitossi FJ, Oertel WH. Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur J Neurosci 2003; 18: 2731 -2742.
147. Vowinckel E, Reutens D, Becher B, Verge G, Evans A, Owens T, Antel JP. PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurosci Res 1997; 50: 345-353.
148. Gao HM, Hong JS, Zhang W, Liu B. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J Neurosci 2002; 22: 782-790.
149. Lopez-Real A, Rey P, Soto-Otero R, Mendez-Alvarez E, Labandeira-Garcia JL. Angiotens in converting enzyme inhibitors reduce oxidative stress and protect dopaminergic neurons in a 6 -hydroxydopamine rat model of parkinsonism. J Neurosci Res 2005; 81: 865-873.
150. Muñoz A, Rey P, Guerra MJ, Mendez-Alvarez E, Soto-Otero R, Labandeira-Garcia JL. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Neuropharmacology 2006; 51: 112-120.
151. Rey P, Lopez-Real A, Sanchez-Iglesias S, Muñoz A, Soto-Otero R, Labandeira-Garcia JL. Angiotensin type-1-receptor antagonists reduce 6- hydroxydopamine toxicity for dopaminergic neurons. Neurobiol Aging 2007; 28: 555-567.
152. Grammatopoulos TN, Jones SM, Ahmadi FA, Hoover BR, Snell LD, Skoch J, Jhaveri VV, Poczobutt AM, Weyhenmeyer JA, Zawada WM. Angiotensin type 1 receptor antagonist losartan, reduces MPTP-induced degeneration of dopaminergic neurons in substantia nigra. Mol Neurodegener 2007; 2: 1.
153. Zawada WM, Banninger GP, Thornton J, Marriott B, Cantu D, Rachubinski AL, Das M, Griffin WS, Jones SM. Generation of reactive oxygen species in 1-methyl-4-phenylpyridinium (MPP+) treated dopaminergic neurons occurs as an NADPH oxidase-dependent two-wave cascade. J Neuroinflammation 2011; 8: 129.
154. Konings CH, Kuiper MA, Bergmans PL, Grijpma AM, van Kamp GJ, Wolters EC. Increased angiotensin- converting enzyme activity in cerebrospinal fluid of treated patients with Parkinson's disease. Clin Chim Acta 1994; 23: 101-106.
155. Lin JJ, Yueh KC, Chang DC, Lin SZ. Association between genetic polymorphism of angiotens in converting enzyme gene and Parkinson disease. J Neurol Sci 2002; 199: 25-29.
156. Becker C, Jick SS, Meier CR. Use of antihypertensives and the risk of Parkinson disease. Neurology 2008; 70: 1438-1444.
157. Ascherio A, Tanner CM. Use of antihypertensives and the risk of Parkinson's disease. Neurology 2009; 72: 578-579.
158. Sarma GR, Kamath V, Mathew T, Roy AK. A case of parkinsonism worsened by losartan: a probable new adverse effect. Mov Disord 2008; 23: 1055.
159. Collier TJ, Lipton J, Daley BF, Palfi S, Chu Y, Sortwell C, Bakay RA, Sladek JR Jr, Kordower JH. Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol Dis 2007; 26: 56-65.
160. Deng XH, Bertini G, Xu YZ, Yan Z, Bentivoglio M. Cytokine-induced activation of glial cells in the mouse brain is enhanced at an advanced age. Neuroscience 2006; 141: 645-661.
161. McCormack AL, Di Monte DA, Delfani K, Irwin I, DeLanney LE, Langston WJ, Janson AM. Aging of the nigrostriatal system in the squirrel monkey. J Comp Neurol 2004; 471: 387-395.
162. Kubis N, Faucheux BA, Ransmayr G, Damier P, Duyckaerts C, Henin D, Forette B, Le Charpentier Y, Hauw JJ, Agid Y, Hirsch EC. Preservation of midbrain catecholaminergic neurons in very old human subjects. Brain 2000; 123: 366- 373.
163. Villar-Cheda B, Valenzuela R, Rodriguez-Perez AI, Guerra MJ, Labandeira-Garcia JL. Agingrelated changes in the nigral angiotensin system enhances proinflammatory and prooxidative markers and 6-OHDA-induced dopaminergic degeneration. Neurobiol Aging 2012; 33: 204. e1-11.
164. Sugama S, Yang L, Cho BP, DeGiorgio LA, Lorenzl S, Albers DS, Beal MF, Volpe BT, Joh TH. Age-related microglial activation in 1-methyl -4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)- induced dopaminergic neurodegeneration in C57BL/6 mice. Brain Res 2003; 964: 288-294.
165. Sohn HY, Raff U, Hoffmann A, Gloe T, Heermeier K, Galle J, Pohl U. Differential role of angiotensin II receptor subtypes on endothelial superoxide formation. Br J Pharmacol 2000; 131: 667-672.
166. Gerhardt GA, Cass WA, Yi A, Zhang Z, Gash DM. Changes in somatodendritic but not terminal dopamine regulation in aged rhesus monkeys. J Neurochem 2002; 80: 168-177.
167. Callier S, Le Saux M, Lhiaubet AM, Di Paolo T, Rostène W, Pelaprat D. Evaluation of the protective effect of oestradiol against toxicity induced by 6-hydroxydopamine and 1-methyl-4- phenylpyridinium ion (MPP+) towards dopaminergic mesencephalic neurones in primary culture. J Neurochem 2002; 80: 307-316.
168. Leranth C, Roth RH, Elsworth JD, Naftolin F, Horvath TL, Redmond DE Jr. Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory. J Neurosci 2000; 20: 8604-8609.
169. Currie LJ, Harrison MB, Trugman JM, Bennett JP, Wooten GF. Postmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol 2004; 61: 886-888.
170. Ragonese P, D'Amelio M, Callari G, Salemi G, Morgante L, Savettieri G. Age at menopause predicts age at onset of Parkinson's disease. Mov Disord 2006; 21: 2211-2214.
171. Ragonese P, D'Amelio M, Savettieri G. Implications for estrogens in Parkinson's disease: an epidemiological approach. Ann N Y Acad Sci 2006; 1089: 373-382.
172. Popat RA, Van Den Eeden SK, Tanner CM, McGuire V, Bernstein AL, Bloch DA, Leimpeter A, Nelson LM. Effect of reproductive factors and postmenopausal hormone use on the risk of Parkinson disease. Neurology 2005; 65: 383- 390.
173. Shulman LM. Is there a connection between estrogen and Parkinson's disease? Parkinsonism Relat Disord 2002; 8: 289-295.
174. Morale MC, Serra PA, L'episcopo F, Tirolo C, Caniglia S, Testa N, Gennuso F, Giaquinta G, Rocchitta G, Desole MS, Miele E, Marchetti B. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration. Neuroscience 2006; 138: 869-878.
175. Tripanichkul W, Sripanichkulchai K, Finkelstein DI. Estrogen down- regulates glial activation in male mice following 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine intoxication. Brain Res 2006; 1084: 28-37.
176. Chen J, Yang S, Hu S, Choudhry MA, Bland KI, Chaudry IH. Estrogen prevents intestinal inflammation after trauma-hemorrhage via downregulation of angiotensin II and angiotensin II subtype I receptor. Am J Physiol Gastrointest Liver Physiol 2008; 295: G1131-1137.
177. Dean SA, Tan J, O'Brien ER, Leenen FH. 17betaestradiol downregulates tissue angiotens in converting enzyme and ANG II type 1 receptor in female rats. Am J Physiol Regul Integr Comp Physiol 2004; 288: R759-766.
178. Nickenig G, Bäumer AT, Grohè C, Kahlert S, Strehlow K, Rosenkranz S, Stäblein A, Beckers F, Smits JF, Daemen MJ, Vetter H, Böhm M. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation 1998; 97: 2197-2201.
179. Liu HW, Iwai M, Takeda-Matsubara Y, Wu L, Li JM, Okumura M, Cui TX, Horiuchi M. Effect of estrogen and AT1 receptor blocker on neointima formation. Hypertension 2002; 40: 451- 457.
180. Tsuda M, Iwai M, Li JM, Li HS, Min LJ, Ide A, Okumura M, Suzuki J, Mogi M, Suzuki H, Horiuchi M. Inhibitory effects of AT1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress. Hypertension 2005; 45: 545-551.
181. Xue B, Pamidimukkala J, Lubahn DB, Hay M. Estrogen receptor-alpha mediates estrogen protection from angiotensin II-induced hypertension in conscious female mice. Am J Physiol Heart Circ Physiol 2007; 292: H1770-1776.
182. Hoshi-Fukushima R, Nakamoto H, Imai H, Kanno Y, Ishida Y, Yamanouchi Y, Suzuki H. Estrogen and angiotensin II interactions determine cardio-renal damage in Dahl salt-sensitive rats with heart failure. Am J Nephrol 2008; 28: 413-423.
183. Rodriguez-Perez AI, Valenzuela R, Villar-Cheda B, Guerra MJ, Lanciego JL, Labandeira-Garcia JL. Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson's disease. Exp Neurol 2010; 224: 517-526.
184. Rodriguez-Perez AI, Valenzuela R, Villar-Cheda B, Guerra MJ, Labandeira-Garcia JL. Different dopaminergic neuroprotection of hormonal replacement therapy in young and aged menopausal rats. Role of the brain angiotensin system. Brain 2012; 135: 124-138.
185. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
186. Clarkson TB, Mehaffey MH. Coronary heart disease of females: lessons learned from nonhuman primates. Am J Primatol 2009; 71: 785- 793.
187. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL, WHI Investigators. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010; 304: 1684-1692.
188. Turgeon JL, McDonnell DP, Martin KA, Wise PM. Hormone therapy: physiological complexity belies therapeutic simplicity. Science 2004; 304: 1269-1273.
189. Turgeon JL, Carr MC, Maki PM, Mendelsohn ME, Wise PM. Complex actions of sex steroids in adipose tissue, the cardiovascular system, and brain: Insights from basic science and clinical studies. Endocr Rev 2006; 27: 575-605.
190. Miller VM, Clarkson TB, Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, Naftolin F, Santoro N. Women, hormones, and clinical trials: a beginning, not an end. J Appl Physiol 2005; 99: 381-383.
191. Miller VM, Black DM, Brinton EA, Budoff MJ, Cedars MI, Hodis HN, Lobo RA, Manson JE, Merriam GR, Naftolin F, Santoro N, Taylor HS, Harman SM. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res 2009; 2: 228-239.
192. Harman SM, Naftolin F, Brinton EA, Judelson DR. Is the estrogen controversy over? Deconstructing the Women's Health Initiative study: a critical evaluation of the evidence. Ann N Y Acad Sci 2005; 1052: 43-56.
193. Buchman AS, Shulman JM, Nag S, Leurgans SE, Arnold SE, Morris MC, Schneider JA, Bennett DA. Nigral pathology and parkinsonian signs in elders without Parkinson disease. Ann Neurol 2012; 71: 258-266.
194. Zijlmans J, Evans A, Fontes F, Katzenschlager R, Gacinovic S, Lees AJ, Costa D. [123I] FP-CIT spect study in vascular parkinsonism and Parkinson's disease. Mov Disord 2007; 22: 1278- 1285.
195. Thanvi B, Lo N, Robinson T. Vascular parkinsonism-- an important cause of parkinsonism in older people. Age Ageing 2005; 34: 114-119.
196. Zijlmans JC, Katzenschlager R, Daniel SE, Lees AJ. The L-dopa response in vascular parkinsonism. J Neurol Neurosurg Psychiatry 2004; 75: 545-547.
197. Rodriguez-Perez AI, Dominguez-Meijide A, Lanciego JL, Guerra MJ, Labandeira-Garcia JL. Dopaminergic degeneration is enhanced by chronic brain hypoperfusion and inhibited by angiotensin receptor blockage. Age (Dordr) 2012.
198. Villar-Cheda B, Sousa-Ribeiro D, Rodriguez-Pallares J, Rodriguez-Perez AI, Guerra MJ, Labandeira-Garcia JL. Aging and sedentarism decrease vascularization and vegf levels in the rat substantia nigra. Implications for Parkinson's disease. J Cereb Blood Flow Metab 2009; 29: 230-239.
199. Koprich JB, Reske-Nielsen C, Mithal P, Isacson O. Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J Neuroinflammation 2008; 5: 8.
200. Garrido-Gil P, Joglar B, Rodriguez-Perez AI, Guerra MJ, Labandeira-Garcia JL. Involvement of PPAR-γ in the neuroprotective and antiinflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease. J Neuroinflammation 2012; 9: 38
201. Villar-Cheda B, Dominguez-Meijide A, Joglar B, Rodriguez-Perez AI, Guerra MJ, Labandeira-Garcia JL. Involvement of microglial RhoA/Rho- Kinase pathway activation in the dopaminergic neuron death. Role of angiotensin via angiotensin type 1 receptors. Neurobiol Dis 2012; 47: 268-279.
202. Doughan AK, Harrison DG, Dikalov SI. Molecular mechanisms of angiotensin II-mediated mitochondrial dysfunction: linking mitochondrial oxidative damage and vascular endothelial dysfunction. Circ Res 2008; 102: 488-496.
203. Kimura S, Zhang GX, Nishiyama A, Shokoji T, Yao L, Fan YY, Rahman M, Suzuki T, Maeta H, Abe Y. Role of NAD(P)H oxidase- and mitochondria- derived reactive oxygen species in cardioprotection of ischemic reperfusion injury by angiotensin II. Hypertension 2005; 45: 860- 866.
204. Wosniak J Jr, Santos CX, Kowaltowski AJ, Laurindo FR. Cross-talk between mitochondria and NADPH oxidase: effects of mild mitochondrial dysfunction on angiotensin II-mediated increase in Nox isoform expression and activity in vascular smooth muscle cells. Antioxid Redox Signal 2009; 11: 1265-1278.
205. Dikalova AE, Bikineyeva AT, Budzyn K, Nazarewicz RR, McCann L, Lewis W, Harrison DG, Dikalov SI. Therapeutic targeting of mitochondrial superoxide in hypertension. Circ Res 2010; 107: 106-116.
206. Rodriguez-Pallares J, Parga JA, Joglar B, Guerra MJ, Labandeira-Garcia JL. The Mitochondrial ATP-Sensitive Potassium Channel Blocker 5- Hydroxydecanoate Inhibits Toxicity of 6- Hydroxydopamine on Dopaminergic Neurons. Neurotox Res 2009; 15: 82-95.
207. Rodriguez-Pallares J, Parga JA, Joglar B, Guerra MJ, Labandeira-Garcia JL. Mitochondrial ATPsensitive potassium channels enhance angiotensin- induced oxidative damage and dopaminergic neuron degeneration. Relevance for aging-associated susceptibility to Parkinson's disease. Age (Dordr) 2012; 34: 863-880.
208. Biber K, Neumann H, Inoue K, Boddeke HW. Neuronal 'On' and 'Off' signals control microglia. Trends Neurosci 2007; 30: 596-602.
209. Greenwood J, Walters CE, Pryce G, Kanuga N, Beraud E, Baker D, Adamson P. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J 2003; 17: 905-907.
210. Honing H, van den Berg TK, van der Pol SM, Dijkstra CD, van der Kammen RA, Collard JG, de Vries HE. RhoA activation promotes transendothelial migration of monocytes via ROCK. J Leukoc Biol 2004; 75: 523-528.
211. Yan J, Zhou X, Guo JJ, Mao L, Wang YJ, Sun J, Sun LX, Zhang LY, Zhou XF, Liao H. Nogo-66 inhibits adhesion and migration of microglia via GTPase Rho pathway in vitro. J Neurochem 2012; 120: 721-731.
212. Bernhart E, Kollroser M, Rechberger G, Reicher H, Heinemann A, Schratl P, Hallström S, Wintersperger A, Nusshold C, DeVaney T, Zorn-Pauly K, Malli R, Graier W, Malle E, Sattler W. Lysophosphatidic acid receptor activation affects the C13NJ microglia cell line proteome leading to alterations in glycolysis, motility, and cytoskeletal architecture. Proteomics 2010; 10: 141-158.